TransMedics Group, Inc. (NASDAQ:TMDX) Stock Has Consensus Target Price of $115.60

TransMedics Group, Inc. (NASDAQ:TMDX) has been given a consensus recommendation of “Hold” by the twelve ratings firms that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and five have assigned a buy rating to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $115.60.

TMDX has been the topic of several research reports. TD Cowen reissued a “buy” rating and set a $120.00 price target on shares of TransMedics Group in a research note on Tuesday, September 8th. Barclays assumed coverage on shares of TransMedics Group in a research note on Wednesday, October 7th. They set an “overweight” rating and a $120.00 price objective for the company. Piper Sandler reaffirmed an “overweight” rating and issued a $100.00 price target (down from $120.00) on shares of TransMedics Group in a research note on Wednesday, August 5th. Weiss Ratings raised shares of TransMedics Group from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, August 31st. Finally, Needham & Company LLC reaffirmed a “buy” rating on shares of TransMedics Group in a research report on Friday, September 11th.

Insider Transactions at TransMedics Group

In related news, Director David Weill purchased 1,336 shares of the company’s stock in a transaction that occurred on Friday, September 11th. The stock was acquired at an average price of $81.63 per share, with a total value of $109,057.68. Following the completion of the purchase, the director directly owned 16,392 shares in the company, valued at $1,338,078.96. This trade represents a 8.87% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 6.90% of the company’s stock.

Hedge Funds Weigh In On TransMedics Group

A number of institutional investors and hedge funds have recently made changes to their positions in TMDX. Putney Financial Group LLC purchased a new stake in shares of TransMedics Group in the third quarter valued at approximately $161,000. Trek Financial LLC bought a new stake in TransMedics Group during the third quarter worth approximately $11,989,000. China Universal Asset Management Co. Ltd. raised its holdings in TransMedics Group by 700.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 800 shares of the company’s stock valued at $67,000 after buying an additional 700 shares in the last quarter. D.A. Davidson & CO. grew its position in TransMedics Group by 1.4% during the 3rd quarter. D.A. Davidson & CO. now owns 16,060 shares of the company’s stock worth $1,340,000 after acquiring an additional 228 shares during the last quarter. Finally, Redmond Asset Management LLC acquired a new stake in shares of TransMedics Group in the 3rd quarter valued at approximately $237,000. 99.67% of the stock is owned by hedge funds and other institutional investors.

TransMedics Group Price Performance

Shares of NASDAQ TMDX opened at $65.99 on Friday. The company has a quick ratio of 6.07, a current ratio of 6.62 and a debt-to-equity ratio of 1.62. The firm’s 50-day simple moving average is $81.65 and its 200 day simple moving average is $94.92. The stock has a market cap of $2.28 billion, a P/E ratio of 16.96, a P/E/G ratio of 0.91 and a beta of 2.14. TransMedics Group has a fifty-two week low of $60.10 and a fifty-two week high of $156.00.

TransMedics Group (NASDAQ:TMDX) last released its earnings results on Tuesday, August 4th. The company reported $0.44 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.06). The business had revenue of $189.95 million during the quarter, compared to analysts’ expectations of $184.00 million. TransMedics Group had a net margin of 22.69% and a return on equity of 15.88%. TransMedics Group’s revenue for the quarter was up 20.7% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.92 EPS. Equities analysts expect that TransMedics Group will post 1.46 EPS for the current year.

About TransMedics Group

TransMedics Group, Inc is a medical technology company focused on improving organ transplantation through systems that preserve and assess donor organs outside the body. The company’s primary platform is the Organ Care System (OCS), a portable, technology-enabled perfusion system designed to maintain organs in a functioning, near-physiologic state during transport and evaluation.

TransMedics offers OCS products for heart, lung and liver transplantation. Its systems are intended to support the use of organs that may not otherwise be suitable for conventional cold-storage methods, potentially expanding the donor pool and providing transplant teams with additional information when evaluating organs for transplantation.

Founded in 1998 and headquartered in Andover, Massachusetts, TransMedics serves transplant centers in the United States and select international markets.